| Aug 14 |
SciSparc Updates Regarding the Status of the AutoMax Merger
|
| Jul 22 |
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
|
| Jul 17 |
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
|
| Jul 16 |
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
|
| Jul 16 |
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
|
| Jul 8 |
SciSparc Signs Non-Binding Letter of Intent to Spin Off Advanced Clinical Stage Pharmaceutical Portfolio
|
| Jul 8 |
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
|
| May 31 |
SciSparc Secures Strategic Advantage with Grant of European Patent
|
